Xofigo® (radium Ra 223 dichloride) is ordered and distributed through a single point of contact distribution model. To order Xofigo or get more information, visit Xofigo.com
Xofigo® (radium Ra 223 dichloride) injection is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch
, or call 1-800-FDA-1088.
For important risk and use information about Xofigo, please see the Full Prescribing Information.
1. Xofigo® (radium Ra 223 dichloride) injection [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; March 2016.